Cidara Therapeutics Inc [CDTX] stock prices are up 7.41% to $1.16 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CDTX shares have gain 26.09% over the last week, with a monthly amount glided 65.88%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 5, April 2024, Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024. In a post published today on Yahoo Finance, – Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study.
From an analyst’s perspective:
Previously, WBB Securities upgraded its rating to Strong Buy on September 22, 2021, and kept the price target unchanged to $6.25. On March 04, 2021, Aegis Capital initiated with a Buy rating and assigned a price target of $9 on the stock. Wedbush upgraded its rating to a Outperform and increased its price target to $4 on September 04, 2019. Citigroup initiated its recommendation with a Buy and recommended $8 as its price target on July 26, 2018. In a note dated April 17, 2017, H.C. Wainwright reiterated an Buy rating on this stock and revised its target price from $18 to $14.
The stock price of Cidara Therapeutics Inc [CDTX] has been fluctuating between $0.59 and $1.48 over the past year. Cidara Therapeutics Inc [NASDAQ: CDTX] shares were valued at $1.16 at the most recent close of the market.
Analyzing the CDTX fundamentals
The Cidara Therapeutics Inc [NASDAQ:CDTX] reported sales of 56.54M for trailing twelve months, representing a drop of -68.79%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -0.56%, Pretax Profit Margin comes in at -0.53%, and Net Profit Margin reading is -0.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -2.65 and Total Capital is -1.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.54.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0367 points at the first support level, and at 0.9134 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2466, and for the 2nd resistance point, it is at 1.3332.
Cidara Therapeutics Inc [CDTX] reported earnings per share of -$0.09 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.16/share, meaning a difference of $0.07 and a surprise factor of 43.80%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.14 per share as compared to estimates of -$0.13 per share, a difference of -$0.01 representing a surprise of -7.70%.
Ratios To Look Out For
It’s worth pointing out that Cidara Therapeutics Inc [NASDAQ:CDTX]’s Current Ratio is 1.62. Further, the Quick Ratio stands at 1.55, while the Cash Ratio is 1.37. Considering the valuation of this stock, the price to sales ratio is 1.86, the price to book ratio is 13.05.
Transactions by insiders
Recent insider trading involved Tari Leslie, CHIEF SCIENTIFIC OFFICER, that happened on Mar 11 ’24 when 21029.0 shares were sold. Chief Medical Officer, Sandison Taylor completed a deal on Mar 11 ’24 to sell 20662.0 shares. Meanwhile, COO & CLO Ward Shane sold 20473.0 shares on Mar 11 ’24.
